Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 10, 2019 9:30 AM - Nov 12, 2019 5:40 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S07] Ideal Conduct and Future Perspectives for Publication by Pharmaceutical Companies

Session Chair(s)

Yuko  Kojima, RPh

Yuko Kojima, RPh

Sr. Executive Director

Eli Lilly Japan K.K., Japan

Company-sponsored publications are one of the most critical sources of medical information to help HCPs decide treatment for a patient. So, it is very important to understand what pharmaceutical companies should do to ensure ethical and effective publications to have the evidence appropriately communicated and to avoid any misconduct. In this session, we will readdress the publication basics such as Good Publication Practice 3 (GPP3) and ICMJE recommendations with international publication experts. We will also discuss current practices and challenges which a Japanese pharmaceutical company faces in a real setting. On top of these, we will touch upon future outlook such as how to involve patients in publications.


Ana  Marušic, MD, PhD

What Journal Editors Expect from the Pharmaceutical Industry?

Ana Marušic, MD, PhD

University of Split School of Medicine, Croatia (Hrvatska)

Professor and Chair, Department of Research in Biomedicine and Health

Audrey  Krolicki, PharmD

Current and Future Publication Practice by Pharmaceutical Company

Audrey Krolicki, PharmD

Astellas Pharma, United States

Executive Director, Head of Medical Information

Ken-ichi  Setsukinai, PhD

Current Status and Issues of Publication Management from Inhouse Perspective

Ken-ichi Setsukinai, PhD


Medical Affairs Division, Medical communication group manager

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.